Clearside Biomedical

Clearside Biomedical R&D Expenses

Delisted

The Research & Development Expenses of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 18.59 M USD. In the previous year, Research & Development Expenses was 20.85 M USD — a change of -10.82% (lower).

R&D Expenses

18.59 MUSD

YoY

-10.82%

Last updated:

Research & Development Expenses of Clearside Biomedical is 2024 18.59 M USD. Research & Development Expenses of Clearside Biomedical was 2023 20.85 M USD. It decreases by -10.82% lower compared to the previous year.

The Clearside Biomedical R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2017
49.05 M USD
Jan 1, 2018
68.29 M USD
Jan 1, 2019
15.66 M USD
Jan 1, 2020
15.07 M USD
Jan 1, 2021
18.54 M USD
Jan 1, 2022
19.63 M USD
Jan 1, 2023
20.85 M USD
Jan 1, 2024
18.59 M USD
The Clearside Biomedical R&D Expenses history
YEARR&D ExpensesYoY
18.59 MUSD-10.82%
20.85 MUSD+6.19%
19.63 MUSD+5.88%
18.54 MUSD+23.03%
15.07 MUSD-3.77%
15.66 MUSD-77.07%
68.29 MUSD+39.23%
49.05 MUSD+152.06%
19.46 MUSD+80.86%
10.76 MUSD+60.84%
6.69 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Research & Development Expenses of Clearside Biomedical is 18.59 M USD in 2024.

Research & Development Expenses of Clearside Biomedical changed from 20.85 M USD to 18.59 M USD, representing a -10.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Clearside Biomedical

All Key Metrics — Clearside Biomedical